Helixon
Beijing
About Helixon
Huashen Zhiyao is a biotechnology company that accelerates novel drug discovery for unmet medical needs. Huashen Zhiyao develops an AI drug development platform and antibody engineering experiment platform to provide researchers with intelligent systems for microscopic molecular calculation, simulation, and design, committing to improving the speed and efficiency of new drug development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $84.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2022)
- Website: helixon.com
- Phone: [email protected].
Industries & Categories
Biotechnology, Medical
Canonical: https://fsome.com/organization/helixon-2205 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.